Henry Schein, Inc.
NASDAQ:HSICMedical - Distribution
-$1.24 today
- Market cap
- $9.47B
- Beta
- 0.82
- P/E (TTM)
- 23.3
- EPS (TTM)
- $3.44
Volume 2.08M
Average 1.39M
HSIC Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Henry Schein, Inc.NASDAQ: HSIC
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development remains negative
Q2 FY2026 research & development was $0, compared with $0 a year earlier. Trailing-twelve-month research & development was $0.
Context
- Research & development amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly research & development holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-27 | 0 | — |
| FY2024 | 2024-12-28 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Research & Development vs competitors
How HSIC compares with its peers on the latest reported figures
- HSIC's LTM Jun 2026 research & development of $0 is the 3rd highest of the 7 companies compared; the peer median is $0.
- Research & development amounts to 0.0% of revenue for HSIC, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $158M | -0.6% | -4.8% | 4.3% | |
| LTM Oct 2026 | $121.8M | +12.2% | +4.4% | 4.2% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| LTM Jun 2026 | $0 | — | +5.0% | 0.0% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| LTM Sep 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding HSIC) | $0 | +5.8% | +4.4% | 0.0% | |
Competitors are the stored peer set for HSIC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 12.4B | 12.65B | 12.34B | 12.67B | 13.18B |
| Cost of Revenue | 8.73B | 9B | 8.69B | 8.91B | 9.34B |
| Gross Profit | 3.67B | 3.65B | 3.65B | 3.77B | 3.84B |
| Gross Margin | 29.6% | 28.9% | 29.6% | 29.7% | 29.1% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 2.82B | 2.71B | 2.94B | 3.04B | 3.08B |
| Operating Expenses | 2.82B | 2.71B | 2.94B | 3.04B | 3.08B |
| Depreciation & Amortization | 209.53M | 212M | 222M | 268M | 311M |
| EBITDA | 1.07B | 977M | 851M | 912M | 1.01B |
| EBITDA Margin | 8.6% | 7.7% | 6.9% | 7.2% | 7.6% |
| Operating Income | 854.81M | 938M | 714M | 729M | 758M |
| Operating Margin | 6.9% | 7.4% | 5.8% | 5.8% | 5.7% |
| Interest Income | 6.45M | 17M | 17M | 24M | 33M |
| Interest Expense | 27.6M | 44M | 87M | 131M | 150M |
| Other Income / Expenses | (4.25M) | (202M) | (158M) | (203M) | (213M) |
| Income Before Tax | 850.56M | 736M | 556M | 526M | 545M |
| Pre-Tax Margin | 6.9% | 5.8% | 4.5% | 4.2% | 4.1% |
| Income Tax Expense | 197.35M | 170M | 120M | 128M | 126M |
| Net Income | 623.91M | 538M | 416M | 390M | 398M |
| Net Margin | 5.0% | 4.3% | 3.4% | 3.1% | 3.0% |
| EPS (Basic) | 4.51 | 3.95 | 3.18 | 3.07 | 3.29 |
| EPS (Diluted) | 4.45 | 3.91 | 3.16 | 3.05 | 3.27 |
| Weighted Avg Shares | 140.09M | 136.06M | 130.62M | 126.79M | 120.81M |
| Weighted Avg Shares (Diluted) | 141.77M | 137.76M | 131.75M | 127.78M | 121.72M |
Henry Schein, Inc.
NASDAQ:HSIC
Intrinsic Alpha fair value
Locked
Current Price
$85.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.